About Us

Advanced Catheter Therapies, an early stage research and development medical device company, has a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis. ACT is developing a revolutionary device for restenosis (re-blockage of blood vessels) and as well as catheters for endovascular debulking (clearing of blocked blood vessels).

The company was founded in 2008 by Dr. Rex Teeslink, M.D., an interventional radiologist, Dirk Hoyns, a medical device engineer, and the Medical Device Development Group (MDDG). Paul J. Fitzpatrick joined the team as CEO in January 2009, and Kevin Dye became vice president of finance and operations in 2010.

Dr. Teeslink, with over 40 years of experience, began his career at a time when the subspecialty of interventional and vascular radiology was in its infancy. This afforded him the opportunity to evaluate and utilize every manufactured device in this arena. Recognizing the need to greatly improve the way in which vascular disease and restenosis were treated led him to help in the development of many of the interventional procedures that are utilized today in this field.

Vascular Disease and Restenosis

Our focus at ACT is on substantially improving patient care and lowering healthcare costs related to vascular disease and restenosis. The company operates as a highly efficient research and development organization, developing its product line through a phased approach.

ACT’s role in product development includes design, IP patent filing, engineering, working prototyping, bench testing, animal testing, and regulatory approvals. Once the device is ready for human trials and/or manufacturing, sales and distribution, ACT will out-license or sell each device technology to a strategic partner.
On November 1, 2011, Atlanta Catheter Therapies announced a name change to Advanced Catheter Therapies.